HomeReleasesBlueCross BlueShield of Tennessee Updates Coverage...
Releases

BlueCross BlueShield of Tennessee Updates Coverage for Liver Elastography

BlueCross BlueShield of Tennessee Updates Coverage for Liver Elastography

Effective July 31, 2026, BlueCross BlueShield of Tennessee has formalized its medical policy regarding noninvasive imaging for chronic liver disease. The insurer affirms that FibroScan remains medically necessary for patient monitoring, while categorizing several competing transient elastography technologies as investigational due to insufficient clinical evidence.

The revised policy draws a sharp line between established diagnostic tools and emerging alternatives. While FibroScan retains its status as a covered medical necessity, the insurer explicitly excludes techniques such as ViTE, represented by systems like Mindray’s Hepatus, and MAP technologies, including Liverscan C. According to Amy Conner, Director of Market Access at Echosens, this distinction helps clinicians navigate an increasingly crowded market by identifying which platforms possess the evidence base required for reimbursement.

For providers, the update clarifies the billing landscape for ultrasound elastography. Exams that incorporate image guidance and formal provider interpretation align with the requirements for CPT code 76981. In instances where these specific diagnostic criteria are not met, the insurer mandates the use of CPT code 91200 for liver elastography billing. These adjustments aim to standardize the evaluation of chronic liver disease across the provider network, ensuring that coverage decisions remain tethered to peer-reviewed clinical validation.

Share:TelegramXFacebook

Read Also

Comments (0)

Leave a comment

No comments yet. Be the first!